Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Alcon Research89 enrolled

Overview

The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Open-angle Glaucoma

Interventions

Anecortave Acetate Sterile Suspension, 30 mg/mLDRUG

Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.

Anecortave Acetate VehicleOTHER

Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of open-angle glaucoma; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pseudoexfoliation; * Pigment dispersion component; * Other protocol-defined exclusion criteria may apply.

Locations (1)

Texas

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP)

Time frame: 3 months

Secondary Outcomes

Percent Treatment Failures

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.